Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): 1-Year results from Phase 3 YOSEMITE and RHINE Trials

Track:
Retina
What:
Paper Presentation | Présentation d'article
Part of:
When:
3:43 PM, Saturday 26 Jun 2021 (8 minutes)

Authors: Geoff Williams, Jeffrey Willis, Zdenka Haskova, David Silverman, Jane Ives, Karen Basu, Hugh Lin.

Author Disclosure Block: G. Williams: Membership on advisory boards or speakers’ bureaus; Name of for-profit or not-for-profit organization(s); Novartis, Bayer, Roche. Membership on advisory boards or speakers’ bureaus; Description of relationship(s); Advisory Boards. Funded grants or clinical trials; Name of for-profit or not-for-profit organization(s); Novartis, Bayer, Roche, Abvie, Chengdu Kanghong Biotech. Funded grants or clinical trials; Description of relationship(s); Clinical Trials. J. Willis: All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Name of for-profit or not-for-profit organization(s); Genentech. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Description of relationship(s); Employee. Z. Haskova: All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Name of for-profit or not-for-profit organization(s); Genentech Inc. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Description of relationship(s); Employee. D. Silverman: All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Name of for-profit or not-for-profit organization(s); F. Hoffmann-La Roche. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Description of relationship(s); Employee. J. Ives: All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Name of for-profit or not-for-profit organization(s); F. Hoffmann-La Roche. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Description of relationship(s); Employee. K. Karen Basu: All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Name of for-profit or not-for-profit organization(s); F. Hoffmann-La Roche. H. Lin: All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Name of for-profit or not-for-profit organization(s); Genentech. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Description of relationship(s); Employee.

Abstract Body:

Purpose: Evidence from Phase 2 study (BOULEVARD), and preclinical models, suggest that dual inhibition of Ang-2 and VEGF-A with faricimab, the first bispecific antibody designed for intraocular use, may synergistically promote vascular stability, leading to improved outcomes beyond intravitreal anti-VEGF monotherapy in patients with DME. The Phase 3 YOSEMITE and RHINE trials are designed to assess the safety, efficacy, and durability of faricimab over aflibercept in DME.
Study Design: YOSEMITE (NCT03622580) and RHINE (NCT03622593) are identical, phase 3, randomized, double-masked, active comparator-controlled trials of faricimab in treatment-naïve and previously anti-VEGF-treated patients with center-involving DME.
Methods: Patients were randomized 1:1:1 to faricimab 6.0 mg every 8 weeks (Q8W), following 6 initial Q4W doses; faricimab 6.0 mg administered per personalized treatment interval (PTI), following a minimum of 4 initial Q4W doses; or aflibercept 2.0 mg Q8W, following 5 initial Q4W doses. The PTI algorithm is a protocol-driven regimen based on the treat-and-extend concept, using prespecified BCVA and anatomical criteria measured at active dosing visits to adjust treatment intervals. Noninferiority, followed by superiority in treatment-naïve patients and then the overall population, of the two faricimab arms over aflibercept was assessed hierarchically. The primary efficacy endpoint was the mean change in BCVA from baseline at 1 year (Week 48, 52, and 56 average). Secondary endpoints include proportion of patients with ≥ 2-step ETDRS-DRSS improvement from baseline, proportion of patients gaining ≥15 ETDRS letters, change from baseline in CST, and proportion of patients in the PTI arm on Q4W, Q8W, Q12W, or Q16W treatment intervals, at 1 year. Safety was assessed by incidence and severity of ocular and non-ocular adverse events.
Results: In the Phase 2 BOULEVARD study, faricimab 6.0 mg Q4W resulted in superior vision gains and greater improvements in diabetic retinopathy severity at Week 24, and demonstrated potential for extended durability in a 16-week off-treatment observation period, over ranibizumab Q4W. YOSEMITE and RHINE are ongoing trials. Year-1 results will be presented at the meeting.
Conclusions: YOSEMITE and RHINE evaluate the safety, efficacy, and durability of faricimab in patients with DME using PTI, a protocol-driven regimen based on treat-and-extend, or Q8W dosing. Year-1 results will be presented at the meeting.

Speaker
Calgary Retina Consultants
Session detail
Allows attendees to send short textual feedback to the organizer for a session. This is only sent to the organizer and not the speakers.
To respect data privacy rules, this option only displays profiles of attendees who have chosen to share their profile information publicly.

Changes here will affect all session detail pages